e-learning
resources
Virtual 2020
Wednesday, 09.09.2020
Thoracic oncology
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Thoracic Cancers International COVID-19 Collaboration (TERAVOLT): Impact of type of cancer therapy and COVID therapy on survival
J. van Meerbeeck (Edegem (Antwerp), Belgium)
Source:
Virtual Congress 2020 – Thoracic oncology
Session:
Thoracic oncology
Session type:
State of the art session
Number:
4948
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. van Meerbeeck (Edegem (Antwerp), Belgium). Thoracic Cancers International COVID-19 Collaboration (TERAVOLT): Impact of type of cancer therapy and COVID therapy on survival. Virtual Congress 2020 – Thoracic oncology
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
Challenges in the management of SCLC
Related content which might interest you:
Late Breaking Abstract - Thoracic Cancers International COVID-19 Collaboration (TERAVOLT): Impact of type of cancer therapy and COVID therapy on survival.
Source: Virtual Congress 2020 – COVID-19 clinical studies
Year: 2020
Survival in lung cancer: Associated factors in Tunisian patients
Source: International Congress 2015 – Thoracic oncology around the world: rare cases and local features
Year: 2015
Maintenance therapy with pemetrexed in non-small-cell lung cancer: Impact on survival
Source: International Congress 2015 – Lung cancer therapy: clinical trials
Year: 2015
Lung cancer after lymphoma: Disease characteristics, detection methods and clinical outcome
Source: Annual Congress 2013 –Other thoracic tumours, particular circumstances and rare cases
Year: 2013
Influence of neoadjuvant therapy to complication rate after surgery for primary lung cancer
Source: International Congress 2016 – Surgical strategy for complex diseases
Year: 2016
Impact of second-line treatment on overall survival of advanced lung adenocarcinoma patients
Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up
Year: 2016
Safety and efficacy of erlotinib in patients with squamous cell lung cancer
Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series
Year: 2014
Prognostic factors for survival in lung cancer
Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer
Year: 2013
Progression vs. pseudo progression in the treatment of squamous NSCLC with nivolumab
Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up
Year: 2016
Comparison of British and American Thoracic Societies’ reintroduction guidelines for anti-tuberculous therapy induced liver injury
Source: Annual Congress 2013 –Tuberculosis and latent tuberculosis infection in subpopulations
Year: 2013
Chemotherapy beyond 3rd line in NSCLC – A retrospective analysis
Source: International Congress 2015 – Lung cancer therapy: clinical trials
Year: 2015
Surgical treatment outcomes on early-stages of non-small-cell lung cancer
Source: International Congress 2015 – Diagnosis and therapy of lung cancer
Year: 2015
Improving survival for NSCLC patients in the national lung cancer audit
Source: International Congress 2015 – Quality management in lung cancer
Year: 2015
Analysis of PET-CT use across a UK cancer network: Are we adhering to NICE guidelines?
Source: International Congress 2015 – Quality management in lung cancer
Year: 2015
Surgical exploration of the mediastinum in non-small cell lung cancer (NSCLC): Adherence to the European Society of Thoracic Surgeons (ESTS) guidelines
Source: Annual Congress 2010 - Quality management for lung cancer patients
Year: 2010
Lung cancer in women: What are particularities?
Source: International Congress 2014 – The epidemiology of respiratory infections and lung cancer
Year: 2014
Clinical and therapeutic characteristics of patients died due to radiation-induced pneumonitis
Source: International Congress 2015 – Lung cancer therapy: clinical trials
Year: 2015
Gene therapy with DDMC-p53 with or without cisplatin and microwave ablation. A future concept for local treatment in lung cancer
Source: International Congress 2015 – Diagnosis and therapy of lung cancer
Year: 2015
Assessment of nutritional status in patients with primary lung cancer
Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series
Year: 2014
Lung cancer in England: Trends in survival over the duration of the national lung cancer audit
Source: Annual Congress 2013 –Epidemiology of respiratory disease
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept